Physician profile
David G Walker
NPI 1205832367
$3,943.98
in general payments reported to CMS, 2019-2025
23 companies · $788 in 2025
The $788 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $251 · 2021: $770 · 2022: $572 · 2023: $445 · 2024: $590 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,823.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,312.40 | 2019-2025 | Airsupra, Farxiga |
| Novo Nordisk INC | $721.02 | 2020-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $496.21 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $215.00 | 2025 | |
| Boston Scientific Corporation | $163.50 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.76 | 2019-2025 | Jardiance |
| Biohaven Pharmaceuticals, INC. | $145.69 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $137.84 | 2022 | |
| Sanofi-Aventis U.S. LLC | $107.30 | 2019 | |
| Abbvie INC. | $74.83 | 2021-2022 | |
| Exact Sciences Corporation | $61.54 | 2024-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $55.66 | 2025 | Korlym |
| Amgen INC. | $52.91 | 2024-2025 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $46.31 | 2024-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Abbott Laboratories | $43.57 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $30.31 | 2023-2024 | Accrufer |
| Genentech USA, INC. | $26.16 | 2019-2020 | |
| Seqirus USA INC | $25.40 | 2024 | Fluad, Flucelvax |
| Cipher Pharmaceuticals US LLC | $17.75 | 2025 | Natroba, Spinosad |
| Kowa Pharmaceuticals America, INC. | $16.13 | 2023 | Livalo |
| Janssen Pharmaceuticals, INC | $15.37 | 2021 | |
| Dexcom, INC. | $15.17 | 2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $15.15 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.